Pilot study of an ACh [acetylcholine]-E inhibitor [pyridostigmine] upon immune activation markers in HIV-1 infected patients receiving highly active antiretroviral therapy (HAART) showing an incomplete immune response
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antiretrovirals; Pyridostigmine
- Indications HIV-1 infections
- Focus Biomarker; Pharmacodynamics
- 14 Nov 2019 Biomarkers information updated
- 04 May 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 04 May 2009 Planned end date changed from 1 May 2008 to 1 Jan 2009 as reported by ClinicalTrials.gov record.